Table 1.

Contributions of non-CYP enzymes to the clearance of drugs approved during 2011–2020 (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm).

Drug name	Drug class or mechanism	UGT	SULT1	AO	CES1	CES2	MAO-A	NAT2	FMO	Amidase	NDA #	Year
Canagliflozin	Sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor	x									204,042	2013
Fostamatinib	Tyrosine kinase inhibitor	x									209,299	2018
Mirabegron	β3-Adrenergic agonist	x									202,611	2012
Nintedanib	Respiratory agent	x									205,832	2014
Safinamide	MAO-B inhibitor	x									207,145	2017
Siponimod	Immunomodulator	x									209,884	2019
Apixaban	Anticoagulant and antiplatelets cardiovascular drug		x								202,155	2012
Opicapone	COMT inhibitor for Parkinson's disease		x								209,510	2020
Crizotinib	Kinase inhibitors for cancer treatment			x							202,570	2011
Idelalisib	Kinase inhibitors for cancer treatment			x							206,545	2015
Edoxaban	Anticoagulant and antiplatelet				x						206,316	2015
Sacubitril	Angiotensin II inhibitor				x						207,620	2015
Selexipag	Vasodilator drug				x						207,947	2015
Sofosbuvir	Antiviral				x						205,834	2014
Tenofovir	Nucleoside reverse transcriptase inhibitor (NRTIs) for treatment of AIDS				x	x					203,100	2012
Telotristat etiprate	Antidiarrheals for gastrointestinal disorder					x					208,794	2017
Safinamide	MAO-A substrate for Parkinson's disease						x				207,145	2017
Retigabine	Anticonvulsant							x			022,345	2011
Eravacycline	Anti-infective								x		211,109	2018
Brivaracetam	Anticonvulsants									x	205,836	2016
Eravacycline	Antibiotics									x	211,109	2018
Safinamide	MAO-B inhibitors									x	207,145	2017

x, enzymes contribute to metabolism of the corresponding drug.